Shots:

• The companies entered into a clinical trial collaboration and supply agreement to evaluate the combination of IDE196 + binimetinib for GNAQ or GNA11 hotspot mutated solid tumors- including MUM- CM & CRC. The study is expected to be initiated in mid-2020
• The clinical study will assess whether inhibition of the MAP-Kinase pathway at two nodes will enhance the response rate- depth and durability of clinical benefit. The companies will form a JDC and shares result of clinical study
• IDEAYA will sponsor the study while Pfizer will provide its binimetinib for the study. IDE196 is a PKC inhibitor and binimetinib is a MEK inhibitor for which Pfizer has exclusive rights in the US and Canada

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: IDEAYA